- Moderna Inc MRNA stock fell on the back of Sweden, pausing use of its COVID-19 vaccine, Reuters reported citing reports of possible rare side effects such as myocarditis.
- The Swedish health agency said that the country would stop using Moderna's shot for people born in 1991 and later.
- The health agency said data pointed to increased myocarditis and pericarditis among vaccinated youths and young adults.
- Related: EMA Says Heart Inflammation Likely Linked To mRNA-Based COVID-19 Vaccines.
- "The connection is especially clear when it comes to Moderna's vaccine Spikevax, especially after the second dose," it said in a statement," adding the risk of being affected was very small.
- The health agency now recommended the Comirnaty vaccine from Pfizer Inc PFE / BioNTech SE BNTX instead.
- The Swedish health agency said people aged 12-15 would only get the Pfizer / BioNTech vaccine earlier this week.
- Related: Moderna's COVID-19 Booster Ok'd In Europe For Immunocompromised.
- Denmark said that, while it used the Pfizer/BioNTech vaccine as its main option for people aged 12-17 years, it had decided to pause vaccination with Moderna shot to people below 18 according to a "precautionary principle."
- "In the preliminary data ... there is a suspicion of an increased risk of heart inflammation when vaccinated with Moderna," the Danish Health Authority said in a statement.
- Related: Is Moderna's COVID-19 Booster Shot Moving Closer To Authorization?
- Price Action: MRNA stock is down 5.95% at $312.36 during the market session on the last check Wednesday.
- Photo by Spencer Davis from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
